Journal
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY
Volume 14, Issue 6, Pages 542-548Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ACI.0000000000000104
Keywords
allergy immunotherapy; Dermatophagoides farinae; Dermatophagoides pteronyssinus; house dust mite; subcutaneous; sublingual
Categories
Ask authors/readers for more resources
Purpose of reviewAlthough systematic reviews have confirmed the effectiveness of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) for the treatment of allergic rhinitis and allergic asthma, a review of studies employing extracts of house dust mites (HDMs) for immunotherapy found no consensus on basic treatment parameters.Recent findingsOver the last 2 years nine additional reports on immunotherapy with HDM extract preparations have been published. Six studies were with SLIT, five for allergic rhinitis and one for allergic asthma. The other three studies were all with SCIT in children with allergic asthma.SummaryThe publication of these nine studies supports the efficacy of HDM-SLIT for allergic rhinitis and asthma and for HDM-SCIT for asthma in children. The reported safety data are also reassuring, especially for SLIT.HDM-SLIT tablets under development will have optimal doses established in large, randomized, placebo-controlled trials. The HDM-SCIT trial in children with allergic asthma confirms the efficacy of a commercialized HDM preparation for injection immunotherapy. However, the information that is presented on dosing in the articles on SLIT-liquid is unsatisfactory, as doses are not presented in a form that the clinician can use to guide their practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available